News
ACAD
16.96
+4.05%
0.66
Implied Volatility Surging for ACADIA Pharmaceuticals (ACAD) Stock Options
NASDAQ · 1d ago
Weekly Report: what happened at ACAD last week (1125-1129)?
Weekly Report · 2d ago
Biotech Alert: Searches spiking for these stocks today
TipRanks · 5d ago
Acadia: Scope Of Company Goes Beyond Recent SAN711 Licensing Deal For ET
Seeking Alpha · 6d ago
ACAD Signs License Deal With Saniona for Rights to Neurology Drug
NASDAQ · 11/27 15:06
JMP Securities Keeps Their Buy Rating on ACADIA Pharmaceuticals (ACAD)
TipRanks · 11/27 05:25
Acadia Pharma Announces License Agreement With Saniona For SAN711
NASDAQ · 11/27 03:26
Acadia Pharmaceuticals in Exclusive License Agreement With Saniona for SAN711
Dow Jones · 11/26 23:07
Acadia signs licensing deal for essential tremor drug candidate
Seeking Alpha · 11/26 22:26
Acadia Pharmaceuticals Announces Exclusive License Agreement With Saniona For SAN711; Under The Terms Of The License Agreement, Saniona Will Receive $28M Upfront Plus Potential Milestone Payments Of Up To $582M
Benzinga · 11/26 21:19
Acadia announces exclusive license agreement with Saniona for SAN711
TipRanks · 11/26 21:15
ACADIA PHARMACEUTICALS INC - SANIONA TO RECEIVE UP TO $147 MILLION FOR DEVELOPMENT AND COMMERCIAL MILESTONES
Reuters · 11/26 21:05
Weekly Report: what happened at ACAD last week (1118-1122)?
Weekly Report · 11/25 09:27
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
Barchart · 11/21 15:05
ACADIA Pharmaceuticals: Strategic Leadership and Growth Prospects Support Buy Rating
TipRanks · 11/21 11:55
Acadia Pharmaceuticals' Operating Chief Involuntarily Terminated Without Cause
Dow Jones · 11/20 22:20
Acadia Pharmaceuticals Announces Leadership Change Amid COO Departure
TipRanks · 11/20 21:55
ACADIA PHARMACEUTICALS INC - ON NOV 18, CO INVOLUNTARILY TERMINATES COO BRENDAN TEEHAN
Reuters · 11/20 21:34
ACADIA Pharmaceuticals: Untapped Potential with Financial Stability and Strategic Growth Opportunities
TipRanks · 11/19 06:56
Weekly Report: what happened at ACAD last week (1111-1115)?
Weekly Report · 11/18 09:27
More
Webull provides a variety of real-time ACAD stock news. You can receive the latest news about Acadia Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About ACAD
Acadia Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has a portfolio of commercial stage products, in-development product opportunities, and research programs that are designed to address unmet needs in CNS disorders and rare diseases. Its pipeline includes NUPLAZID (pimavanserin), DAYBUE (trofinetide), ACP-101, ACP-204, and Antisense Oligonucleotide (ASO) Programs. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. Trofinetide is a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 (IGF-1) designed to treat the core symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function.